Although the effects were present in mice without Bruton tyrosine kinase, mice that received acalabrutinib, a specific Bruton tyrosine kinase inhibitor for 4 weeks had AF, showing an off-target side effect [49]. This evidence concerns the gene BTK and atrial fibrillation.